DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Pfizer (NYSE: PFE)



company name or ticker
Company Photos
(Click to zoom)

XLV, PSL: Big ETF Outflows

4 Pharmaceutical Companies Leading the Breast Cancer Fight

Healthcare Deals: Big Pharma, Megamergers and IPOs

Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio

Big Pharma Q1 Earnings Beat Put Pharma ETFs In Focus

The 4 Stocks That Weighed on the DJIA on Wednesday

iShares Core High Dividend ETF Experiences Big Inflow

Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Pfizer (PFE) Lag

Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Pfizer (PFE) Lags

2 Under-the-Radar Updates Pfizer Inc.'s Shareholders Need to Know About

Pfizer's size has become a problem for the investing community. During its recent first-quarter conference call, for example, the pharma giant barely had enough time to update investors on two key experimental drugs, and made no mention of numerous others. Here's a deeper look at just two under-the-radar clinical updates that shareholders need to know about right now.

Is There A Silver Lining For Pfizer Amid Challenging Conditions?